Dr Dorff presented early data for the first 12 CAR-T trial patients at the American Society of Clinical Oncology (ASCO) meeting this weekend. For those of you interested in wading through the data, here's the link to the abstract
meetings.asco.org/abstracts...
The short version is that early results are promising, and modifications to the procedure allows them to control cystitis snd Cytokine Release Syndrome (CRS).